The brand-new edition of the 2026 Clinical Research Report examines key therapy areas and deep dives into the latest advances in precision and personalised medicine, while shining a light on how researchers are tackling the complexities of diseases like cancer and cardiovascular conditions. This year, a key theme was the expanding role of AI, which is unlocking new possibilities by integrating multi-omics data with clinical records, resulting in greater insight into patterns, breakthroughs in predictive biomarkers, and smarter patient stratification, improving the effectiveness of treatments.
The 2026 report also delves into the role of AI in improving clinical trial processes, such as recruitment and retention, which have historically been significant hurdles. AI technologies like TrialMatchAI and AIM-MASH are revolutionising patient-to-trial matching and endpoint consistency, leading to more efficient and reliable trials. Alongside these technical advances, the report also provides timely analysis of the evolving regulatory landscape, including recent US FDA guidelines that signal growing convergence around the use of AI in drug development and personalised medicine.
Further exclusive content includes insights from Barbara Lopez Kunz, CEO of Caidya, who discusses the need for a holistic redesign of clinical research to address inefficiencies and enhance support for cross-border trials and global representation in trial data.
The 2026 Clinical Research Report paints a compelling picture of a sector on the verge of transformation, where technological innovation and strategic collaboration are setting the stage for the future of clinical research.
Download now for an exclusive look at what’s in store for the industry in 2026 and beyond.
